MIV in polymer-free DES (drug-eluting stent) trial:
This article was originally published in Clinica
As part of its bid to bring to market technology that it claims could lead to improved drug-eluting stents (DESs), MIV Therapeutics has performed the first-in-man implant of its polymer-free DES. The MIVT Pilot Trial, which is being conducted in Brazil, will evaluate the safety and efficacy of the device in patients with single de novo lesions in their native coronary arteries. The product combines the company's GenX coronary stent with one of its hydroxyapatite polymer-free drug-eluting systems that is 700 nanometers thin. The Atlanta, Georgia firm believes its new class of polymer-free DESs could provide patients with superior outcomes.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.